Skip to contentC
Chemed Corp
C
CHEChemed Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$411.01M$411.01Mderived+17.4% vs Q4 2023 Net Income$90.32M$90.32Mderived+0.3% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Chemed Corp · CIK 19584 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$113,878,000+2.2% Operating Cash Flowderived$164,913,000+51.9% Free Cash Flowderived$152,152,000+57.2% Margins · derivedOperating margin27.7%−4.1 pt vs Q4 2023
Net margin22.0%−3.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 28, 2025 · 59 d after period end